CTI-1601

About Larimar Therapeutics

Larimar Therapeutics is dedicated to addressing rare diseases with significant unmet medical needs through its proprietary intracellular protein replacement platform. Its lead candidate, CTI-1601, is a recombinant fusion protein designed to deliver human frataxin to the mitochondria of patients with Friedreich's ataxia, a debilitating and life-shortening neurodegenerative disorder. The company is advancing CTI-1601 through clinical development while exploring its platform's potential for other rare diseases. Larimar's strategy centers on demonstrating proof-of-concept in Friedreich's ataxia to validate its technology and create value for patients and shareholders.

Therapeutic Areas

Other Friedreich's Ataxia Drugs